GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
ONCOTHYREON (ONTY) [hlAlert]

Rating:
Mkt Outperform
ONTY
up 175.78 %

ONCOTHYREON (ONTY) rated Mkt Outperform with price target $10 by Rodman & Renshaw

Posted on: Monday,  Apr 25, 2011  2:25 PM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform ONCOTHYREON (NASDAQ: ONTY) on 04/25/2011. Previously Rodman & Renshaw rated Mkt Outperform ONCOTHYREON (NASDAQ: ONTY) on
03/18/2009., when the stock price was $1.28. Since then, ONCOTHYREON has gained 175.78% as of 01/14/2016's recent price of $3.53.
If you would have followed the previous Rodman & Renshaw's recommendation on ONTY, you would have gained 175.78% of your investment in 2493 days.

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company?s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon?s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company?s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/25/2011 2:25 PM Buy
None
4.63 10.00
as of 12/30/2011
1 Week down  -1.30 %
1 Month up  8.59 %
3 Months up  26.75 %
1 YTD up  132.51 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/18/2009 2:25 PM Buy
None
1.28 4.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy